Comparative Pharmacology
Head-to-head clinical analysis: HUMATIN versus KANAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMATIN versus KANAMYCIN SULFATE.
HUMATIN vs KANAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
None Documented
None Documented
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic